Prognostic Significance of Orotate Phosphoribosyltransferase Activity in Bladder Carcinoma

Cancer

Volumn 100, Issue 4, 2004, Pages 723-731

  Mizutani, Yoichi ^a   Wada, Hiromi ^b   Fukushima, Masakazu ^c   Yoshida, Osamu ^b   Nakanishi, Hiroyuki ^a   Li, Yong Nan ^a   Miki, Tsuneharu ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 Fluorouracil; Bladder carcinoma; Orotate phosphoribosyltransferase; Thymidine kinase; Thymidylate synthase

Indexed keywords

ANTINEOPLASTIC AGENT; DNA; FLUOROURACIL; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; RNA; THYMIDINE KINASE; THYMIDYLATE SYNTHASE;

ADULT; AGED; ARTICLE; BLADDER CARCINOMA; CHEMOSENSITIVITY; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OROTATE PHOSPHORIBOSYLTRANSFERASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 0842304365     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11955     Document Type: Article

References (29)

1. Kubota Y, Hosaka M, Fukushima S. Prophylactic oral UFT therapy for superficial bladder cancer. Cancer. 1993;71:1842-1845.
2. Ueda T, Iguchi A, Sagiyama K, Kyushu University Urological Oncology Group. Early intravesical instillation of Adriamycin with oral administration of 5-fluorouracil after transurethral resection for superficial bladder cancer: Preliminary results. Cancer Chemother Pharmacol. 1987;20:841-843.
3. Pinedo HM, Peters GJ. 5-Fluorouracil: biochemistry and pharmacology. Clin Oncol. 1988;6:1653-s1664.
4. Santi DV, McHenry CS, Sommer H. Mechanisms of interaction of thymidylate synthase with 5-fluorodeoxyuridine. Biochemistry. 1974;13:471-480.
5. Shirasaka T, Shimamoto Y, Fukushima M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res. 1993;53:4004-4009.
6. Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996;87:212-220.
7. Kanai F, Kawakami T, Hamada H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res. 1998;58:1946-1951.
8. Inaba M, Sawada H, Sadata A, Omata M. Circumvention of 5-fluorouracil resistance in human stomach cancer cells by uracil phosphoribosyltransferase gene transduction. Jpn J Cancer Res. 1999;90:349-354.
9. Mizutani Y, Wada H, Ogawa O, et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma. Cancer. 2001;92:510-518.
10. Mizutani Y, Wada H, Yoshida O, et al. Significance of thymidylate synthase activity in renal cell carcinoma. Clin Cancer Res. 2003;9:1453-1460.
11. Mizutani Y, Wada H, Yoshida O, Fukushima M, Kamoi K, Miki T. Prognostic significance of thymidine kinase activity in bladder cancer. Cancer. 2002;95:2120-2125.
12. Mizutani Y, Wada H, Yoshida O, Fukushima M, Nakao M, Miki T. Significance of thymidine kinase activity in renal cell carcinoma. J Urol. 2003;169:706-709.
13. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by Adriamycin. Cancer Res. 2000;60:2912-2918.
14. Mizutani Y, Bonavida B, Koishihara Y, Akamatsu K, Ohsugi Y, Yoshida O. Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum (II) by anti-interleukin-6 monoclonal antibody or anti-interleukin-6-receptor monoclonal antibody. Cancer Res. 1995;55:590-596.
15. Mizutani Y, Nakanishi H, Yoshida O, Fukushima M, Bonavida B, Miki T. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL-mediated apoptosis by subtoxic concentrations of 5-fluorouracil. Eur J Cancer. 2002;38:167-176.
16. Mizutani Y, Wada H, Yoshida O, et al. Significance of dihydropyrimidine dehydrogenase activity in renal cell carcinoma. Eur J Cancer. 2003;39:541-547.
17. Danenberg PV. Thymidylate synthase: a target enzyme in cancer chemotherapy. Biochem Biophys Acta. 1977;473:73-92.
18. Navalgund LG, Rossano C, Muench AJ. Cell cycle regulation of thymidylate synthase gene expression in cultured mouse fibroblasts. J Biol Chem. 1980;255:7386-7390.
19. O'Neil KL, Grigsby RV, Fairbairn DW. Thymidine kinase: the future in breast cancer prognosis. Breast. 1995;4:79-83.
20. Foekens JA, Romain S, Look MP, Martin PM, Klijn JGM. Thymidine kinase and thymidylate synthase in advanced breast cancer: response to tamoxifen and chemotherapy. Cancer Res. 2001;61:1421-1425.
21. Ikenaka K, Fukushima M, Nakamura H, Okamoto M, Shirasaka T, Fujii S. Metabolism of pyrimidine nucleotides in various tissues and tumor cells from rodents. Jpn J Cancer Res. 1981;72:590-597.
22. Lamm DL, van der Meijden APM, Mizutani Y, et al. Intravesical chemotherapy and immunotherapy: How do we assess their effectiveness and what are their limitations and uses? Int J Urol. 1995;2:23-35.
23. Heney, NM, Ahmed S, Flanagan MJ, et al. Superficial bladder cancer. Progression and recurrence. J Urol. 1983;130: 1083-1088.
24. Pestalozzi BC, Peterson HF, Gelber RD, et al. Prognostic importance of thymidylate synthase expression in early breast cancer. J Clin Oncol. 1997;15:1923-1931.
25. Diasio RB, Lu Z. Dihydropyrimidine dehydrogenase activity and fluorouracil chemotherapy. J Clin Oncol. 1994;12:2239-2242.
26. Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res. 1987;47:2203-2206.
27. Mizutani Y, Wada H, Fukushima M, et al. Significance of dihydropyrimidine dehydrogenase activity in bladder cancer. Eur J Cancer. 2001;37:569-575.
28. Fujii R, Seshimo A, Kameoka S. Relationships between the expression of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase and cell proliferative activity and 5-fluorouracil sensitivity in colorectal carcinoma. Int J Clin Oncol. 2003;8:72-78.
29. Isshi K, Sakuyama T, Gen T, et al. Predicting 5-FU sensitivity using human colorectal cancer specimens: comparison of tumor dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferase activities with in vitro chemosensitivity to 5-FU. Int J Clin Oncol. 2002;7:335-342.